Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies.


Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
04 2019
Historique:
received: 21 11 2017
revised: 09 02 2018
accepted: 03 03 2018
pubmed: 5 4 2018
medline: 20 3 2019
entrez: 5 4 2018
Statut: ppublish

Résumé

To systematically identify and validate published colorectal cancer risk prediction models that do not require invasive testing in two large population-based prospective cohorts. Models were identified through an update of a published systematic review and validated in the European Prospective Investigation into Cancer and Nutrition (EPIC) and the UK Biobank. The performance of the models to predict the occurrence of colorectal cancer within 5 or 10 years after study enrolment was assessed by discrimination (C-statistic) and calibration (plots of observed vs predicted probability). The systematic review and its update identified 16 models from 8 publications (8 colorectal, 5 colon and 3 rectal). The number of participants included in each model validation ranged from 41 587 to 396 515, and the number of cases ranged from 115 to 1781. Eligible and ineligible participants across the models were largely comparable. Calibration of the models, where assessable, was very good and further improved by recalibration. The C-statistics of the models were largely similar between validation cohorts with the highest values achieved being 0.70 (95% CI 0.68 to 0.72) in the UK Biobank and 0.71 (95% CI 0.67 to 0.74) in EPIC. Several of these non-invasive models exhibited good calibration and discrimination within both external validation populations and are therefore potentially suitable candidates for the facilitation of risk stratification in population-based colorectal screening programmes. Future work should both evaluate this potential, through modelling and impact studies, and ascertain if further enhancement in their performance can be obtained.

Identifiants

pubmed: 29615487
pii: gutjnl-2017-315730
doi: 10.1136/gutjnl-2017-315730
pmc: PMC6580880
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't Systematic Review Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

672-683

Subventions

Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C57955/A24390
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A19170
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 24390
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 16491
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 25004
Pays : United Kingdom
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M501712/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C570/A16491
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom

Informations de copyright

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Déclaration de conflit d'intérêts

Competing interests: TS received a studentship from the Medical Research Council (MR/M501712/1). DCM is supported by a Cancer Research UK Population Research Fellowship (C57955/A24390). KJA received a research grant from the German Research Foundation (DFG) (AL 1784/3-1), KEB received research grants from Cancer Research UK (C570/A16491) and the Medical Research Council (MR/M012190/1); no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; KGMM is director of Research of a large (around 500 employees) research and teaching institute within his University Medical Center. They perform both investigator-driven and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of the members of staff receive unrestricted grants for research projects from a number of companies. It is their explicit policy to work with several companies and not to focus on one or two industrial partners. He receives no personal payment from any industrial partner.

Références

Gut. 2015 Oct;64(10):1637-49
pubmed: 26041752
JAMA. 1982 May 14;247(18):2543-6
pubmed: 7069920
J Natl Cancer Inst. 2011 Dec 21;103(24):1827-39
pubmed: 22158127
Stat Med. 2009 Jul 10;28(15):1982-98
pubmed: 19452569
Cancer Causes Control. 2000 Jul;11(6):477-88
pubmed: 10880030
PLoS Med. 2014 Oct 14;11(10):e1001744
pubmed: 25314315
J Clin Oncol. 2009 Feb 10;27(5):686-93
pubmed: 19114701
Cancer Epidemiol. 2010 Oct;34(5):534-41
pubmed: 20554262
Prev Med. 2000 Oct;31(4):323-34
pubmed: 11006057
Cancer Prev Res (Phila). 2016 Jan;9(1):13-26
pubmed: 26464100
BMJ. 2012 Sep 18;345:e5900
pubmed: 22990994
Genet Med. 2011 May;13(5):385-91
pubmed: 21270638
Am J Med. 2007 Mar;120(3):257-63
pubmed: 17349449
Stat Methods Med Res. 2018 Nov;27(11):3505-3522
pubmed: 28480827
PLoS One. 2014 Feb 12;9(2):e88079
pubmed: 24533067
BMJ. 2016 May 16;353:i2416
pubmed: 27184143
J Behav Med. 2015 Dec;38(6):837-50
pubmed: 26280755
Biostatistics. 2020 Apr 1;21(2):236-252
pubmed: 30203058
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2543-52
pubmed: 25087576
J Am Board Fam Med. 2014 Jan-Feb;27(1):42-55
pubmed: 24390885
J Clin Epidemiol. 2004 Apr;57(4):332-40
pubmed: 15135833
Public Health Nutr. 2002 Dec;5(6B):1113-24
pubmed: 12639222
Stat Med. 2012 Jul 10;31(15):1543-53
pubmed: 22344892
J Clin Oncol. 2009 Feb 10;27(5):694-8
pubmed: 19114700
Br J Cancer. 2015 Jun 30;113(1):142-9
pubmed: 26110973
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Cochrane Database Syst Rev. 2013 Oct 01;(9):CD009259
pubmed: 24085634
Clin Chem. 2009 May;55(5):994-1001
pubmed: 19282357

Auteurs

Todd Smith (T)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

David C Muller (DC)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Karel G M Moons (KGM)

Julius Center for Health Sciences and Primary Care, Umc Utrecht, Utrecht University, Utrecht, The Netherlands.

Amanda J Cross (AJ)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Mattias Johansson (M)

International Agency for Research on Cancer (IARC), Genetic Epidemiology Group, Lyon, France.

Pietro Ferrari (P)

Nutritional Methodology and Biostatistics Group (NMB), International Agency for Research on Cancer, Lyon, France.

Guy Fagherazzi (G)

Inserm U1018, Gustave Roussy, Universite Paris-Sud, Villejuif, France.

Petra H M Peeters (PHM)

Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Gianluca Severi (G)

Inserm U1018, Gustave Roussy, Universite Paris-Sud, Villejuif, France.

Anika Hüsing (A)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Rudolf Kaaks (R)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Anne Tjonneland (A)

Danish Cancer Society Research Center, Copenhagen, Denmark.

Anja Olsen (A)

Danish Cancer Society Research Center, Copenhagen, Denmark.

Kim Overvad (K)

Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark.

Catalina Bonet (C)

Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Barcelona, Spain.

Miguel Rodriguez-Barranco (M)

CIBER de Epidemiologia y Salud Publica (CIBERESP), Escuela Andaluza de Salud Publica, Madrid, Spain.

Jose Maria Huerta (JM)

Murcia Regional Health Council, IMIB-Arrixaca, CIBER de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.

Aurelio Barricarte Gurrea (A)

Navarra Public Health Institute, CIBER de Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.

Kathryn E Bradbury (KE)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Antonia Trichopoulou (A)

Hellenic Health Foundation, Athens, Greece.

Christina Bamia (C)

Hellenic Health Foundation, Athens, Greece.

Philippos Orfanos (P)

Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, WHO Collaborating Center for Nutrition and Health, National and Kapodistrian University of Athens, Athens, Greece.

Domenico Palli (D)

Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy.

Valeria Pala (V)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Paolo Vineis (P)

Italian Institute for Genomic Medicine, Turin, Italy.

Bas Bueno-de-Mesquita (B)

Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

Bodil Ohlsson (B)

Department of Internal Medicine, Lund University, Skane University Hospital, Malmo, Sweden.

Sophia Harlid (S)

Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden.

Bethany Van Guelpen (B)

Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden.

Guri Skeie (G)

Department of Community Medicine, Faculty of Health Sciences, University of Tromso, The Arctic University of Norway, Tromso, Norway.

Elisabete Weiderpass (E)

Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway.

Mazda Jenab (M)

Nutritional Epidemiology Group, International Agency for Research on Cancer, Lyon, France.

Neil Murphy (N)

Nutritional Epidemiology Group, International Agency for Research on Cancer, Lyon, France.

Elio Riboli (E)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Marc J Gunter (MJ)

Nutritional Epidemiology Group, International Agency for Research on Cancer, Lyon, France.

Krasimira Jekova Aleksandrova (KJ)

Nutrition, Immunity and Metabolism Start-up Lab, Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrucke, Germany.

Ioanna Tzoulaki (I)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH